JAMA 2018; 320: 43-52
The HPV FOCAL Randomized Clinical Trial
Question Does cervical cancer screening using primary cervical human papillomavirus (HPV) testing compared with cytology result in a lower likelihood of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) at 48 months?
Findings In this randomized clinical trial that included 19 009 women, screening with primary HPV testing resulted in significantly lower likelihood of CIN3+ at 48 months compared with cytology (2.3/1000 vs 5.5/1000).
Meaning HPV-based screening resulted in lower likelihood of CIN3+ than cytology after 48 months, but further research is needed to understand long-term clinical outcomes as well as cost-effectiveness.